Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00050778 · ClinicalTrials.gov registry record · Phase 2
A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis
A Phase 2 study, sponsored by Genzyme, a Sanofi Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 334
- Enrollment target
NCT00050778 is a Phase 2 study that has completed, run by Genzyme, a Sanofi Company. The registered enrollment target is 334 participants.
The verdict
NCT00050778, a Phase 2 study, has completed, sponsored by Genzyme, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 334 participants
- Enrollment target
Study Summary
This was a Phase II, randomized, open-label, rater-blinded, three-arm study comparing two different doses of alemtuzumab (Lemtrada™) and one dose of subcutaneous (SC) interferon beta-1a (Rebif®) in participants with early, active relapsing-remitting multiple sclerosis (MS) who had not been previously treated with MS therapies other than steroids. The study was conducted for an initial period of 3 years and a follow-up to 5 years or more.
Interventions
- BIOLOGICAL Interferon beta-1a
- BIOLOGICAL Alemtuzumab 12 mg
- BIOLOGICAL Alemtuzumab 24 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 334 participants |
| Start Date | 2002-12 |
| Est. Completion | 2010-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00050778
The ClinicalTrials.gov registry entry for NCT00050778 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 334 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genzyme, a Sanofi Company, which has 196 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Interferon beta-1a is the first listed.
NCT00050778 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00050778 about?
NCT00050778 is a clinical study titled "A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis". This was a Phase II, randomized, open-label, rater-blinded, three-arm study comparing two different doses of alemtuzumab (Lemtrada™) and one dose of subcutaneous (SC) interferon beta-1a (Rebif®) in participants with early, active relapsing-remitting multiple sclerosis (MS) who had not been previousl...
What is the current status of trial NCT00050778?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 334 participants. The study started on 2002-12. Estimated completion is 2010-01.
What interventions are being tested in trial NCT00050778?
The interventions under investigation include: Interferon beta-1a (BIOLOGICAL), Alemtuzumab 12 mg (BIOLOGICAL), Alemtuzumab 24 mg (BIOLOGICAL).
Who is sponsoring clinical trial NCT00050778?
This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.